Given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.
The Seraseq Trisomy 13 Female Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.
Matched (or related) maternal-fetal Trisomy 13 (or Patau Syndrome) male sample compatible with a broad range of NIPT assay methods.
Proprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference.
Offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples).
Long shelf-life and lot-to-lot consistency with high-quality materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality checks.
Customization of fetal fraction, concentration, and material formulation (either in plasma or fragmented DNA in buffer format) available on request.
Seraseq Trisomy 13 Female-Matched Reference Material